Quick Answer
VACCINEX, INC. reported Diluted EPS of $8.88 per share (loss) for fiscal year 2024.
VACCINEX, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$8.88 | +79.7% |
| 2023 | -$43.68 | +55.5% |
| 2022 | -$98.05 | -12470.5% |
| 2021 | -$0.78 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$2.83 | +81.4% | +8.7% |
| June 30, 2024 | -$3.10 | +87.4% | -5.4% |
| March 31, 2024 | -$2.94 | +85.9% | +80.7% |
| September 30, 2023 | -$15.25 | -813.2% | +37.9% |
| June 30, 2023 | -$24.54 | -18776.9% | -17.5% |
| March 31, 2023 | -$20.89 | -17308.3% | -1150.9% |
| September 30, 2022 | -$1.67 | -882.4% | -1184.6% |
| June 30, 2022 | -$0.13 | +38.1% | -8.3% |
- VACCINEX, INC. showed an increase of +79.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, VACCINEX, INC.’s diluted eps has declined by 1038.5% (from $0.78 per share (loss) to $8.88 per share (loss)).
- The most recent figure is from VACCINEX, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: